Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line-Reference-Cited by-同舟云学术

Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line

Published:2010-02 Issue:2 Volume:222 Page:401-410
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Chevanne Marta,Zampieri Michele,Caldini Riccardo,Rizzo Angela,Ciccarone Fabio,Catizone Angela,D'Angelo Carmen,Guastafierro Tiziana,Biroccio Anna,Reale Anna,Zupi Gabriella,Caiafa Paola

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference71 articles.

1. Ultrastructural localization of filamentous actin within neuronal interphase nuclei in situ;Amankwah;Exp Cell Res,1994

2. The PARP superfamily;Ame;Bioessays,2004

3. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression;Augustin;J Cell Sci,2003

4. Poly(ADP-ribosyl)ation, PARP, and aging;Beneke;Sci Aging Knowledge Environ,2004

5. The multifunctional nucleolus;Boisvert;Nat Rev Mol Cell Biol,2007

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphorylation within Intrinsic Disordered Region Discriminates Histone Variant macroH2A1 Splicing Isoforms—macroH2A1.1 and macroH2A1.2;Biology;2021-07-13

2. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency;Proceedings of the National Academy of Sciences;2020-07-10

3. The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells;Cancers;2020-06-19

4. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials;Journal of Cancer Research and Clinical Oncology;2019-11-30

5. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD;Cancer Letters;2019-07